* BioMarin Pharmaceutical Inc BMRN.OQ reported quarterly
adjusted earnings of 64 cents per share for the quarter ended
December 31, higher than the same quarter last year, when the
company reported EPS of 18 cents. The mean expectation of
twenty eight analysts for the quarter was for earnings of 53
cents per share. Wall Street expected results to range from 43
cents to 74 cents per share.
* Revenue rose 15.6% to $747.31 million from a year ago;
analysts
expected $713.44 million.
* BioMarin Pharmaceutical Inc's reported EPS for the quarter
was
64 cents.
* The company reported quarterly net income of $124.94
million.
* BioMarin Pharmaceutical Inc shares had fallen by 1.3% this
quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 1.2%
in the last three months.
* In the last 30 days, there have been no negative revisions
of
earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 22 "strong buy" or "buy," 7
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"
Wall Street's median 12-month price target for BioMarin
Pharmaceutical Inc is $94.50
This summary was machine generated from LSEG data February 19 at
10:01 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2024 0.53 0.64 Beat
Sep. 30 2024 0.52 0.55 Beat
Jun. 30 2024 0.35 0.56 Beat
Mar. 31 2024 0.35 0.46 Beat